A question to Dew (and anyone wanting to reply)...What is your take on the Lomucin data? I just can't see what could have been taken as so negative as to drive the stock down so much. I am a teacher, and work with a ten-year-old with CF. Her mom is so on top of all that is going on in the world of CF, and the fact that it received little research funding until celebrities like Boomer Esiason got involved (his son has CF). She is estatic about the Lomucin results, as it provides hope for better treatment. She lives with the thought in the back of her mind that she will have but 30 years to get to know her daughters (her 13 year old has CF as well), and wants those years to be as pleasant as life can be with such a deadly disease. Knowing her desperation for "something" to help, and her positive response to teh results posted by Lomucin makes me believe that it was not truly the disappointment with the results that drove the stock down, but rather the failure for GENR to produce Squal-type (97% stable or improved) results that drove investors away. What are your thoughts? Is Lomucin still a potential winner, or will it (as some have predicted) be set aside now in pursuit of time better spent on Squalamine?
TIA,
Frank
